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Abstract
Parkinson’s disease (PD) and Huntington’s disease (HD) are progressive chronic neurodegenerative disorders that are accompanied by
a considerable impairment of the motor functions. PD may develop for familial or sporadic reasons, whereas HD is based on a definite
genetic mutation. Nevertheless, the pathological processes involve oxidative stress and glutamate excitotoxicity in both cases. A num-
ber of metabolic routes are affected in these disorders. The decrease in antioxidant capacity and alterations in the kynurenine pathway,
the main pathway of the tryptophan metabolism, are features that deserve particular interest, because the changes in levels of neuroac-
tive kynurenine pathway compounds appear to be strongly related to the oxidative stress and glutamate excitotoxicity involved in the
disease pathogenesis. Increase of the antioxidant capacity and pharmacological manipulation of the kynurenine pathway are therefore
promising therapeutic targets in these devastating disorders.
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Introduction
Parkinson’s disease (PD) is a chronic progressive neurodegener-
ative disorder [1] that exhibits increasing prevalence with aging.
On average, it affects about 2 in 1000 people [2–4]. Only about
10% of the cases reveal a familial background; the remaining 90%
are considered to be sporadic with uncertain aetiology, which
draws attention to the role of possible environmental risk factors
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(reviewed in [5]). The main clinical features of PD, including 
resting tremor, rigidity, brady- and hypokinesia and postural 
instability, develop in consequence of the complex dysfunction of
the motor network, with crucial roles for the alterations in the
basal ganglia circuits (reviewed in [6]). The main underlying
pathological hallmark is a preferential loss of brain stem 
catecholaminergic, and especially mesencephalic dopaminergic
neurons in the substantia nigra pars compacta (SNpc) and the
development of intracellular inclusions called Lewy bodies [7].
The resulting dopamine deficiency, apparent mainly in the stria-
tum, means that the brain is no longer capable of sufficient motor
function control (reviewed in [6]).
Huntington’s disease (HD) is likewise a chronic progressive
neurodegenerative disease [8], observed in the middle-aged. In
contrast with PD, it is genetically determined by an autosomal
dominantly inherited definite single mutation in the IT15 gene 
coding for the huntingtin protein [9]. The prevalence of HD is
rather low relative to that of PD; it affects only about 5 in 100,000
people [10–13]. The clinical features of HD are characterized by
cognitive, psychiatric and motor symptoms (reviewed in [14, 15]).
In view of the motor symptoms, the typical loss of coordination of
the voluntary movements and the appearance of involuntary
movements (such as chorea and dystonia) evolve. Further, a pro-
gressive gait impairment also develops, manifested in brady- and
hypokinesia [16, 17]. The pathological alterations are mainly seen
in the central nervous system (CNS), and especially in the caudate
nucleus, the putamen and the deeper layers of the cerebral cortex
[18]. The loss of -aminobutyric acidergic (GABAergic) medium-
sized spiny neurons (MSNs) in the striatum (caudate nucleus 
putamen) is the most pronounced feature [19–21], resulting in a
dysfunction of the basal ganglia circuits, and leading to the develop-
ment of the characteristic symptoms (reviewed in [22]).
The role of mitochondrial impairment
and oxidative stress in 
neurodegeneration
Background
The mitochondria take part in both physiological and pathological
processes, such as energy supply, signalling, Ca2-homeostasis,
cell cycle regulation, apoptosis, free radical generation, thermoge-
nesis, development and aging (reviewed in [23, 24]; Fig. 1). The
electrons arising from the oxidation of the reduced coenzymes
nicotinamide adenine dinucleotide (NAD) and flavin adenine din-
ucleotide reduce molecular oxygen (O2) predominantly to H2O, but
1–2% of the O2 is incompletely reduced, producing the superox-
ide anion (O2.). In the event of the dysfunction of one or more
respiratory chain complexes, the production of O2. is enhanced.
Although O2. itself is only moderately damaging, it is highly reac-
tive [25]. It can be transformed to hydrogen peroxide (H2O2), a
process catalysed by manganese superoxide dismutase, or it can
interact with nitric oxide, providing the highly toxic peroxynitrite
anion. Under physiological conditions, H2O2 is broken down by
glutathione peroxidase or catalase, but if H2O2 is present in excess
amount, it can react with transition metal ions (e.g. Fe2) in the
Fenton reaction, producing another highly toxic and reactive
metabolite, the hydroxyl radical. Besides the mitochondria (the
electron transport chain; ETC) as a major source of free radicals,
other free radical-producing pathways involve participation of the
enzymes xanthine oxidase, monoamine oxidase, cytochrome P450,
myeloperoxidase, nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase, etc. In contrast with other organs, the brain is
more sensitive to lesion-provoking reactive oxygen species
because its O2 demand is high, it contains high concentrations of
polyunsaturated lipids and its antioxidant capacity is relatively low
(reviewed in [26]). There is evidence that the mitochondria play
important roles in both necrotic and apoptotic cell death (reviewed
in [27, 28]). It is important that the occurrence of necrosis or
apoptosis depends on the severity of the pathological stimuli 
[29, 30]. These stimuli, such as oxidative stress, a Ca2 overload,
or ATP depletion, can lead to the formation of mitochondrial per-
meability transition (MPT) pores, a process strongly influenced by
the Bcl-2 family proteins (reviewed in [31]). The presence of these
pores allows the release of cytochrome-c into the cytosol, where
it forms an essential part of the apoptosome, which is composed
of cytochrome-c, apoptotic protease activating factor 1 and procas-
pase 9 [32]. The result is the activation of caspase-9, which then
processes and activates other caspases, leading to the biochemical
execution of the cells. It should be mentioned that caspase-
independent cell death pathways also exist (reviewed in [33]).
Parkinson’s disease
The observation that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP), a product of meperidine analogue synthesis, can cause
the development of chronic parkinsonism [34, 35] drew attention
to the involvement of a mitochondrial dysfunction in PD, for 
1-methyl-4-phenylpyridinium ion (MPP), the toxic metabolite of
MPTP [36, 37], has been shown to be capable of the selective 
inhibition of complex I of the mitochondrial ETC [38, 39]. Later, a
significant decrease in complex I activity was observed in the sub-
stantia nigra and platelets of patients with idiopathic PD [40, 41],
though the currently available experimental data suggest some
inconsistency (reviewed in [42]). Nevertheless, the possible role
of exposure to pesticides (with consequent complex I inhibition
and/or reactive oxygen intermediate (ROI) generation) in the
development of idiopathic PD (reviewed in [43]) provides further
evidence of the crucial role of a mitochondrial dysfunction in the
disease pathogenesis. Indeed, the proved Fe2 accumulation in
PD SNpc appears to be a factor aggravating the oxidative damage
(reviewed in [44–46]). In consequence of genetic mutations, the
deteriorated function of several gene products (e.g. -synuclein,
parkin, phosphatase and tensin homologue induced putative
kinase 1 [PINK1], high-temperature requirement protein A2
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(HtrA2)/Omi, DJ-1, leucine-rich repeat kinase 2 [LRRK2] and
mitochondrial DNA [mtDNA] polymerase 1 [POLG1]) can 
additionally contribute to the development of PD by affecting the
mitochondria too (Fig. 1), amongst other subcellular compart-
ments (reviewed in [42, 47, 48]). The mitochondrial accumulation
of -synuclein under pathological conditions results in decreased
complex I activity and the increased production of ROI in human
dopaminergic neurons [49]. The decrease in parkin function may
result in a reduced mitochondrial antioxidant capacity [50]. PINK1
is able reduce the cytochrome c release from the mitochondria by
phosphorylating tumour necrosis factor receptor-associated 
protein 1, thereby inhibiting oxidative stress-induced apoptosis.
Furthermore, PINK1 has been shown to be able to phosphorylate
both parkin [51] and HtrA2/Omi [52]; the regulation of the prote-
olytic activity of the latter may result in resistance to mitochondrial
stress. DJ-1 acts as an atypical peroxiredoxin-like peroxidase and
its dysfunction results in impaired mitochondrial ROI scavenging
[53]. The available data [54] support the possibility of LRRK2
action at the mitochondria, but the mechanism has not yet 
been clarified. Mutations in POLG1 render mtDNA more vulnerable
to oxidative damage, resulting in a mitochondrial dysfunction, 
and thus these mutations may also be associated with the 
development of PD [55].
Huntington’s disease
An early finding suggestive of the involvement of a mitochondrial
dysfunction in the development of HD was a decreased activity of
succinate dehydrogenase (complex II of the ETC) in post-mortem
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Fig. 1 Oxidative stress and mitochondrial impairment in PD and HD (for details see the text). 3-NP: 3-nitropropionic acid; ADP: adenosine diphosphate;
ATP: adenosine triphosphate; CI-IV: mitochondrial ETC complexes I-IV; CAT: catalase; cyt: cytochrome; FADH2: reduced flavin adenine 
dinucleotide; FexSy: iron-sulfur cluster; FMNH2: reduced flavin mononucleotide; GPX: glutathione peroxidase; GSH: reduced glutathione; GSSG: oxidized 
glutathione; H2O2: hydrogen peroxide; HtrA2: high-temperature requirement protein A2; mNOS: mitochondrial nitric oxide synthase; MPT: mitochondrial
permeability transition; mtDNA: mitochondrial deoxyribonucleic acid; MPP: 1-methyl-4-phenylpyridinium ion; · NO: nitric oxide; O2.: superoxide anion;
·OH: hydroxyl radical; ONOO: peroxynitrite anion; Q: oxidized coenzyme Q10; ·QH: semiquinone coenzyme Q10; QH2: reduced coenzyme Q10; PINK: phos-
phatase and tensin homologue-induced putative kinase 1; POLG1: mtDNA polymerase 1; SOD: superoxide dismutase.
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HD brains [56]. It was later observed that a plant/fungal toxin, 
3-nitropropionic acid (3-NP), which is capable of the irreversible
inhibition of succinate dehydrogenase [57], causes extrapyramidal
symptoms due to food poisoning [58]. This toxin and the reversible
enzyme inhibitor malonate [59] were therefore widely applied in the
animal modelling of HD [60–62]. Mutant huntingtin has been
shown to be able to bind directly to mitochondria, thereby altering
their normal function [63] (Fig. 1). The impaired mitochondrial
Ca2 handling [64] and the repression of transcription factors, e.g.
that responsible for peroxisome proliferator-activated receptor 
coactivator 1- (involved in the regulation of gene expression
related to mitochondrial biogenesis and respiration) [65], are
certainly associated with the mitochondrial dysfunction in HD.
Glutamate excitotoxicity 
in neurodegeneration
Background
The toxic effects of glutamate, the main excitatory amino acid 
in the brain, were first observed in 1957 [66], and the term 
glutamate-induced excitotoxicity was introduced by Olney in 1969
[67]. Besides their role in physiological signal transduction, the
ionotropic and metabotropic glutamate receptors take part in
pathological excitotoxic processes too (reviewed in [68]; Fig. 2).
The N-methyl-D-aspartate (NMDA) receptors (NMDARs) seem to
play the central role in excitotoxicity. The available data suggest
that the activation of NMDARs (which facilitates the entry of
cations, and in particular Ca2, into the neurons) at the extrasy-
naptic site is neurotoxic, whereas synaptic NMDAR activation 
promotes neuronal survival [69]. A conventional NMDAR is com-
posed of 2 NMDAR subunit 1s (NR1s) and 2 NMDAR subunit 2s
(NR2s), forming a heterotetramer. The NR1s form the ion channel,
whereas the NR2s (NR2A-D) have more of a regulatory and refin-
ing role. It has been shown that the NR2B-containing NMDARs
predominate at the extrasynaptic site [70], and there is accumu-
lating evidence that glutamate-induced excitotoxicity is mainly
mediated by these NR2B-containing NMDAR channels [71]. The
-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)
receptors (AMPARs) are composed of a combination of GluR1–4
subunits, whereas the kainate receptors consist of subunits
GluR5–7. The cation permeability profile shows Ca2 permeability
for the AMPARs too, with the exception of those containing the
GluR2 subunit. Conversely, the kainate receptors are mostly
impermeable to Ca2. The activation of AMPARs and kainate
receptors can be associated with both NMDAR function and dys-
function by inducing relief of the Mg2 blockade of the NMDAR
channel. The metabotropic glutamate receptors (mGluR1–8) can
be classified into three groups; their functions are mainly linked to
G-proteins. The activation of group I mGluRs (mGluR1 and
mGluR5) results in intracellular Ca2 mobilization through inositol
triphosphate (IP3) production, leading to IP3 receptor 1 (IP3R1)
activation on the endoplasmatic reticulum (ER) [72, 73]. This can
accompany the pathological Ca2 signalling characteristic of gluta-
mate excitotoxicity. The activation of group II mGluRs
(mGluR2–3) and group III mGluRs (mGluR4, mGluR6–8) leads to
the downstream inhibition of voltage-dependent Ca2 channels
[74], thereby decreasing glutamate release. The dysfunction or
down-regulation of these receptors may result in an enhanced
release of glutamate. The alterations in glutamate uptake mediated
by glutamate transporters (EAAT1–5: excitatory amino acid trans-
porter 1–5), and especially EAAT1 [glutamate aspartate trans-
porter (GLAST)] and EAAT2 [glutamate transporter-1 (GLT-1)], may
also result in an elevation of extracellular glutamate concentration
accompanying the excitotoxic process (reviewed in [75]; Fig. 2).
However, this elevation is not absolutely necessary for
excitotoxicity. An energy impairment due to a mitochondrial
dysfunction and/or oxidative stress can also lead to partial mem-
brane depolarization, resulting in relief of the Mg2 blockade of the
NMDAR channel (Fig. 2). Thus, even in physiological concentra-
tions, glutamate can evoke downstream events such as a Ca2
overload and free radical generation, inducing a self-propagating
process [76]. The downstream events evoked by a Ca2 overload
certainly involve mitochondrial Ca2 sequestration with a conse-
quential impairment of the mitochondrial function, ER stress,
pathological overactivation of several types of kinases and/or phos-
phatases, proteases (e.g. caspases and calpains), neuronal nitric
oxide synthase (nNOS), endonucleases, phospholipases and trans-
glutaminases, leading to detrimental effects (reviewed in [77]).
Parkinson’s disease
A recently published paper [78] dealing with the dysregulation of
glutamate homeostasis in the mouse SNpc due to chronic MPTP
treatment provided evidence of glutamate excitotoxicity involve-
ment in PD pathogenesis secondary to a mitochondrial dysfunc-
tion (commented in [79]). Neurons in the SNpc possess glutamate
receptors and receive glutamatergic input from the subthalamic
nucleus (the main input), cerebral cortex, amygdala and peduncu-
lopontine and laterodorsal tegmental nuclei (reviewed in [80]).
The metabolic compromise leads to a decrease in striatal
dopaminergic innervation, resulting in overactivation of the sub-
thalamic nucleus. This causes an increase in glutamate release
onto the compromised dopaminergic neurons in the SNpc
(reviewed in [81]). Hence, the excitotoxic cascade further worsens
the neurodegenerative process, inducing a vicious cycle.
Huntington’s disease
The results of kainic acid experiments suggested that glutamate
excitotoxicity may play an important role in the development of HD
[82, 83]. Subsequent experiments with ibotenic acid [84] and
quionolinic acid (QUIN) [85, 86] furnished evidence in support of
this. To explain the selective impairment of the MSNs, it should be
borne in mind that they receive a massive glutamatergic input from
© 2011 The Authors
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the cortex [87] and the thalamus (reviewed in [88]). As the NMDA
receptors are to be found in especially high amount on the spines
of the MSNs [89], these neurons are rather sensitive to glutamate
[90, 91], which explains the extremely extensive loss of striatal
neurons expressing NMDARs [92]. Furthermore, the expression
pattern of the receptor subunits differs from those of the other 
striatal neurons [89, 93], as the extrasynaptic NMDARs of MSNs
preferentially contain the NR2Bs [94, 95]. The expression of
mutant huntingtin can sensitize the NR2B-containing NMDARs 
[96, 97], thereby aggravating the excitotoxic process [98] (Fig. 2).
Additionally, the polyglutamine expansion has been found to inter-
fere with the ability of huntingtin to interact with the post-synaptic
density protein of 95 kD (PSD95) [99], a structural link between
nNOS and NMDARs [100], which also results in the sensitization of
NMDARs. Indeed, the glutamate uptake is reduced in HD [101],
and the experimental data suggest that the reduced expression of
mGluR2s may lead to an increase in glutamate release [102],
ensuring the possibility of enhanced activation through the sensi-
tized NMDARs. Further, mutant huntingtin can increase Ca2
release from the ER, by binding to the IP3R1s [103].
The kynurenine pathway
Historical overview
L-Kynurenine (L-KYN) is a central intermediate in the main path-
way of the tryptophan (TRP) metabolism [104]; it was first identi-
fied in rabbit urine [105]. More than 95% of TRP is metabolized
through kynurenines [106]. This pathway is responsible for the
production of nicotinic acid [107], a major component of NAD
and nicotinamide adenine dinucleotide phosphate (NADP) coen-
zymes. L-KYN can be metabolized in three distinct ways to
kynurenic acid (KYNA), anthranilic acid (ANA) and 3-hydroxy-L-
kynurenine (3-OH-L-KYN). KYNA, which has been identified in dog
urine [108], is a side-product of the main metabolic route [109],
while ANA and 3-OH-L-KYN, first identified in 1941 and in 1949,
respectively [110, 111], can be further metabolized in some steps
through an important intermediate, QUIN [112, 113], to NAD in
a common pathway (Fig. 3). As regards the role of kynurenines in
the CNS, it is important to highlight that L-KYN is present in the
© 2011 The Authors
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Fig. 2 The pathomechanism of glutamate
excitotoxicity influenced by the neuroactive
kynurenines (for details see the text). 3-
OH-L-KYN: 3-hydroxy-L-kynurenine; 7-
nAChR: 7-nicotinic acetylcholine receptor;
AMPAR: -amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid receptor; EAAT1–2:
excitatory amino acid transporter 1–2; ER:
endoplasmic reticulum; Glu: L-glutamate;
IP3R1: inositol triphosphate receptor 1;
kainate R: kainate receptor; KYNA: kynurenic
acid; mGluRI-III: group I-III metabotropic
glutamate receptors; NMDAR: N-methyl-D-
aspartate receptor; nNOS: neuronal nitric
oxide synthase; QUIN: quinolinic acid.
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mammalian brain tissue in a concentration of around 200 ng/g. A
total of 40% of it is formed locally, and 60% is taken up from the
periphery [114, 115] as a consequence of its being able to cross
the blood–brain barrier [116, 117] by the large neutral amino acid
carrier, a process studied in detail by Fukui et al. [118]. The
metabolites have also been detected in the mammalian brain [115,
119], in which KYNA, 3-OH-L-KYN and QUIN are commonly
referred to as neuroactive kynurenines (reviewed in [120–122]).
The potential role of kynurenines in depression was suggested in
1973 [123], but the first direct evidence of neuroactive properties,
such as convulsive and stimulatory effects, was demonstrated
only in 1978 [124].
The biosynthesis of neuroactive kynurenines
KYNA is produced from its precursor, L-KYN, in an irreversible
transamination by the action of four subtypes of kynurenine
© 2011 The Authors
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Fig. 3 The kynurenine pathway of the tryp-
tophan metabolism. NAD: nicotinamide
adenine dinucleotide.
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aminotransferases (KATs; reviewed in [125]): KAT-I-II [126], 
KAT-III [127] and mitochondrial aspartate aminotransferase
(mitAAT, also called KAT-IV) [128]. KAT-II has been demonstrated
to be the main KYNA-producing enzyme in the rat and human
brains, whereas in the mouse brain KAT-II surprisingly possesses
the lowest activity and mitAAT the highest [128]. The KATs are
abundantly expressed in the astrocytes [129], but only weak gran-
ular staining can be seen in the neurons [130]. The development
of KAT-II-specific antibodies revealed that the expression of this
enzyme subtype is confined entirely to the astrocytes [131]. 3-OH-
L-KYN is formed by the action of kynurenine 3-hydroxylase [132],
whereas QUIN is produced by 3-hydroxyanthranilate 3,4-dioxyge-
nase [133]. This branch of the kynurenine pathway is mainly local-
ized in the microglia and macrophages [134], whereas astrocytes
do not express kynurenine 3-hydroxylase, but only 3-hydroxyan-
thranilate 3,4-dioxygenase [129].
Neuroactive kynurenines: sites of action
KYNA exerts broad-spectrum endogenous antagonism on ionotropic
excitatory amino acid receptors [135] (Fig. 2). In micromolar 
concentrations, it acts as a competitive antagonist at the strych-
nine-insensitive glycine-binding site of the NMDAR [136] and 
displays weak antagonistic effects on the AMPARs and kainate
receptors [137]. KYNA has been found to be capable of facilitating
AMPAR responses in low (nanomolar to micromolar) concentra-
tions [138], but the concentration range is controversial: KYNA in
micromolar concentrations has recently been shown to have neu-
roinhibitory effects, whereas in nanomolar concentrations it was
claimed to be a facilitator [139]. In addition to its direct effects on
glutamate receptors, KYNA non-competitively blocks the 7-nico-
tinic acetylcholine receptors [140], presynaptic activation of which
is involved in the regulation of glutamate release [141]. It has been
reported that, through activation at the G protein-coupled receptor
GPR35, KYNA can elicit IP3 production and Ca2 mobilization
[142], but the role of this phenomenon is questionable as regards
the CNS, because GPR35 exhibits a limited expression in the brain
and a relatively high KYNA concentration is necessary for activa-
tion. With respect to the KATs, it is interesting that the neuronal
expression of KAT-I appears to have effects on developmental
processes, such as programmed cell death [143]. QUIN is a weak,
but specific competitive agonist of the NMDAR subgroup contain-
ing the NR2A and NR2B subunits, with low receptor affinity [144].
There are 2 mechanisms via which it can cause excitotoxicity mod-
ulating the glutamatergic system: the direct activation of NMDARs
[145] or the release and uptake inhibition of glutamate [146, 147]
(Fig. 2). The production of ROI [148] and lipid peroxydation due to
QUIN also contribute to its neurotoxic effects [149]. The deleteri-
ous effects of 3-OH-L-KYN are mediated by free radicals and not
glutamate receptors [150, 151] (Fig. 2). Some of its detrimental
actions may be due to its metabolite, 3-hydroxyanthranilic acid,
which readily undergoes auto-oxidation with the production of O2
[152], and it has also been shown to be neurotoxic [153].
Neuroactive kynurenines 
in neurodegenerative disorders
Parkinson’s disease
The involvement of kynurenine pathway abnormalities in the
pathogenesis of PD is suggested by the findings that 3-OH-L-KYN
concentrations have been found to be elevated in the frontal cor-
tex, putamen and SNpc of patients with PD, probably contributing
to the oxidative damage [154]. Conversely, KYNA concentrations
are decreased. Accordingly, a reduction in KAT-I in the SNpc of
mice has been observed after MPTP treatment [155].
Furthermore, administration of 6-hydroxydopamine (a free radical
generator in catecholaminergic neurons) considerably diminishes
not only tyrosine hydroxylase, but also KAT-I immunoreactivity in
the remaining SNpc neurons [156]. In rat cerebral cortical slices,
MPP appreciably decreased KAT-II activity, with the resulting
depletion of KYNA [157].
Huntington’s disease
There is a seeming imbalance of the tryptophan metabolism in
the striatum in different stages of the disease. A relative decrease
in KYNA level and reduced activity of KATs have been demon-
strated in the striatum of HD patients [158–160]. The cere-
brospinal fluid level of KYNA has also been observed to be
decreased in HD [161]. The elevation in QUIN concentration in
the early stages correlates well with the increased activity of its
producing enzyme, 3-hydroxyanthranilate 3,4-dioxygenase, in HD
brains [162]. The fact that the intrastriatal injection of QUIN is
highly applicable for the animal modelling of HD [85, 86, 163]
well supports its pathogenetic role in HD development (reviewed
in [164]). In correlation with the findings detailed above, young
mice with the targeted deletion of KAT-II, showing decreased
KYNA and normal 3-OH-L-KYN and QUIN concentrations, dis-
played an increased vulnerability to the intrastriatal injection of
QUIN as compared with the wild-type controls, suggesting the
importance of KYNA in controlling the neurotoxicity of QUIN
[165]. The striatal concentration of 3-OH-L-KYN changes in par-
allel with the QUIN level in HD [160, 166], and it has been shown
to potentiate the neurotoxic effects of QUIN in the rat striatum
[167]. After 3-NP treatment, the activity of KAT-I is reduced most
markedly in the striatum of the rat brain, suggesting a link
between the metabolic disturbances and an altered tryptophan
metabolism in HD [168]. Furthermore, the use of rat cerebral cor-
tical slices proved that the activities of KAT-I and KAT-II were
decreased [157]. The results of a yeast genomic screen indicated
that deletion of the KYNA-producing enzyme enhances mutant
huntingtin-mediated toxicity, whereas it is ameliorated mainly by
the deletion of 3-OH-L-KYN, but also by that of the QUIN-produc-
ing enzyme [169].
© 2011 The Authors
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Endogenous neuroprotection in
Parkinson’s and Huntington’s diseases
Background
PD is one of the few neurodegenerative disorders for which effec-
tive symptomatic therapies are available, whereas in HD, the pro-
posed symptomatic therapies are few and have limited effects. The
main aim of preclinical and clinical studies in this field is to
achieve neuroprotection (preservation of the neuronal structure
and function) or at least to provide highly effective symptomatic
treatment. Amongst the therapeutic strategies, a popular approach
is to attain neuroprotection by the exogenous administration of
endogenously occurring natural substances or their derivatives
with slight modifications. L-3,4-dihydroxyphenylalanine (L-DOPA),
the compound most widely used as symptomatic therapy in PD, is
a good example of this approach. Although there have been
numbers of preclinical and clinical studies on both PD and HD
(reviewed in [170–173]), we mention here only the forms of
endogenous neuroprotection confined to the prevention of oxida-
tive stress, energy impairment and glutamate excitotoxicity.
L-carnitine
L-carnitine plays a role in the mitochondrial exchange of fatty acids;
it has direct or indirect antioxidant properties (reviewed in [174]). It
has proved to be protective in cell culture against MPP [175], and
its derivative, acetyl-L-carnitine, also exerts beneficial effects in the
MPTP model of PD in primates [176], and in a cellular toxin model
of PD [177]. Although L-carnitine suppresses 3-NP-induced MPT
[178], and is neuroprotective in a transgenic mouse model of HD
[179], low-dose acetyl-L-carnitine administration in a double-blind,
placebo-controlled study showed no benefit [180].
L-carnosine
L-carnosine (-alanyl-L-histidine) is a dipeptide with demonstrated
antioxidant, antiglycator and metal chelator properties (reviewed in
[181]). In a pilot study, L-carnosine increased the efficacy of 
L-DOPA treatment in PD patients [182]. In a transgenic mouse
model of HD, L-carnosine was unable to improve the survival or the
motor performance of mice significantly (our unpublished data).
Coenzyme Q10
Coenzyme Q10 is a lipid-soluble benzoquinone that functions as an
electron transporter in the ETC and as an antioxidant. Coenzyme Q10
has also been demonstrated to be effective in the MPTP model of
PD [183] and in the transgenic mouse models of HD [184, 185].
Whereas low-dose administration was ineffective [186], higher
doses of coenzyme Q10 exerted beneficial effects in early PD
patients in a phase II, multicentre, randomized, parallel-group,
placebo-controlled, double-blind, dosage-ranging clinical trial [187]
and in a monocentre, parallel-group, placebo-controlled, double-
blind trial [188]. Surprisingly, a later multicentre, randomized, par-
allel-group, placebo-controlled, double-blind, stratified, single-dose
trial in mid-stage PD did not indicate any significant amelioration
[189]. A randomized, placebo-controlled, phase III trial was recently
initiated. A multicentre, randomized, parallel-group, double-blind
trial [Coenzyme Q10 And Remacemide Evaluation in Huntington's
Disease (CARE-HD)] was unable to prove any significant effect on
the functional decline in early HD, in contrast with an apparent ame-
lioration tendency [190]. This might be due to underdosing; the
Pre2CARE study has revealed that higher doses of coenzyme Q10
are reasonably well tolerated [191]. A larger study (2CARE) is cur-
rently ongoing for the re-evaluation of coenzyme Q10 in HD.
Creatine
Creatine kinase and its substrates creatine and phosphocreatine
take part in the buffering of intracellular energy reserves (reviewed
in [192]) and in the inhibition of MPT activation [193]. The exoge-
nous administration of creatine proved effective in the MPTP model
of PD [194] and the 3-NP, malonate [195] and transgenic mouse
models [196, 197] of HD. Nevertheless, a randomized, double-
blind phase II trial in early PD [198, 199] and a placebo-controlled
randomized pilot trial [200] did not indicate any robust clinical
benefit. A phase III, long-term (5 year follow-up), multicentre,
double-blind, placebo-controlled study [The National Institutes of
Health Exploratory Trials in Parkinson Disease Long-term Study 1
(NET-PD LS1)] is currently ongoing. As regards HD, creatine was
not found to be significantly effective either in a 2 year open label
pilot study [201, 202] or in a placebo-controlled pilot trial [203],
likewise in PD. A high-dose phase III creatine trial started in 2008.
Cysteamine/cystamine
Cysteamine, an antioxidant, is capable of the prevention of lipid
peroxidation and can exert beneficial effects through its action on
enzymes responsible for the maintenance of an antioxidant milieu
or energy preservation [204, 205]. Its oxidized form, cystamine,
exerts a transglutaminase inhibitory effect (reviewed in [206]). An
early study was unable to detect any protective effect of cysteamine
in the MPTP model [207], but it has recently been proved that
lower doses of both cysteamine and cystamine show efficacy [208,
209]. Treatment with cystamine afforded neuroprotection in trans-
genic mouse models of HD [210–212]. A phase I dose finding and
tolerability study [Phase I dose finding and tolerability study of
cysteamine (Cystagon) in Huntington's disease (CYTE-I-HD)] has
already been carried out with cysteamine in HD patients [213].
Eicosapentaenoic acid
Eicosapentaenoic acid (EPA) is an essential n-3 polyunsaturated
fatty acid that targets the mitochondrial function, especially by
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acting on peroxisome proliferator activated receptors (reviewed in
[214]). It has been shown that the administration of polyunsatu-
rated fatty acid mixtures containing EPA improves dyskinesias and
reverses weight loss in HD patients [215] and is beneficial in a
transgenic mouse model of HD [216]. A randomized, double-
blind, placebo-controlled study also demonstrated beneficial
effects [217]. Although treatment with the ethyl ester of EPA
(ethyl-EPA) improved the motor dysfunction in a transgenic
mouse model of HD [218], and also led to an MRI and neuropsy-
chological improvement [219] and a significant reduction in brain
atrophy, particularly in the caudate and thalamus [220], a random-
ized, double-blind, placebo-controlled study indicated no benefit
[221]. At present, The Huntington Study Group is conducting a
multicentre, randomized, double-blind, placebo-controlled trial
with ethyl-EPA [randomized controlled trial of ethyl-eicosapen-
taenoic acid in Huntington disease (TREND-HD)]. The preliminary
data revealed no efficacy after 6 months [222].
-lipoic acid
-lipoic acid is a disulfide compound that serves as a coenzyme
for mitochondrial pyruvate dehydrogenase and -ketoglutarate
dehydrogenase complexes. It exerted beneficial effects in the
transgenic mouse model of HD [223] and in a cellular toxin model
of PD [177].
Pyruvate
Pyruvate is the end-metabolite of glycolysis and serves as an energy
substrate. Pyruvate and its simple derivative ethyl-pyruvate pro-
vided protection against MPP toxicity in vitro [224, 225], but we
did not observe any protection against MPTP in mice. Pyruvate also
exerted neuroprotective effects in the QUIN rat model of HD [226].
Taurine
Taurine is a -amino acid with antioxidant properties (reviewed in
[227]). Although it has been found to be protective in the 3-NP
model of HD [228], we did not observe any beneficial effects either
in the MPTP model of PD, or in a transgenic mouse model of HD
(our unpublished data).
Tocopherol
-tocopherol (the predominant form of vitamin E in the tissues
and in supplements) is a lipid-soluble antioxidant which, despite
the great expectations, was reported to be ineffective both in ani-
mal MPTP models of PD [207, 229], and in PD patients in the
large, randomized, placebo-controlled Deprenyl And Tocopherol
Antioxidative Therapy Of Parkinsonism (DATATOP) study [230].
However, it has also been shown that -tocopherol is capable of
attenuating 6-hydroxydopamine lesions [231] and iron-induced
nigral neuron loss [232]. Furthermore, a pilot trial of high-dose -
tocopherol and ascorbate demonstrated beneficial effects in PD
patients [233]. Nevertheless, a double-blind, placebo-controlled
study did not confirm the efficacy of high-dose -tocopherol in HD
patients, though it would be beneficial for patients early in the
course [234]. Interestingly, -tocopherol (the predominant form
of vitamin E in the diet) effected a considerably larger attenuation
than the statistically ineffective -tocopherol as concerns MPTP-
induced dopamine loss [235].
L-KYN/KYNA
From a therapeutic aspect, enhancement of the effects of KYNA
would be a successful therapeutic strategy providing protection
against the effects of neurotoxic 3-OH-L-KYN and QUIN. This may
be achieved by administration of the KYNA precursor L-KYN.
Thus, a combination of the blood–brain barrier-penetrable L-KYN
with nicotinylalanine, an agent that inhibits both kynurenine 3-
hydroxylase and kynureninase activity, and with probenecid, an
inhibitor of organic acid transport for enhancement of the brain
KYNA concentration, exerted protective effects in the SNpc against
both NMDA and QUIN-induced excitotoxicity [236], and in the
striatum against QUIN-mediated neurotoxicity [237], possibly via
the elevated level of KYNA. However, the co-administration of
probenecid seems necessary to achieve a considerably elevated
KYNA level in the field of interest. Although L-KYN alone was able
to induce amelioration in animal models of cerebral ischemia
[238, 239], it is mainly used in combination with probenecid to
achieve neuroprotection (e.g. in a migraine model: [240]).
However, it has recently been shown that probenecid alone can
mitigate the alterations in that migraine model [241]. Further,
probenecid is protective in a transgenic mouse model of HD [242],
whereas L-KYN alone is ineffective (our unpublished data). In an
MPTP model of PD, we did not find any protection with pure L-
KYN either. Nevertheless, the available data suggest that L-KYN in
combination with probenecid is perhaps capable of enhancing
neuroprotection in chronic neurodegenerative disorders.
Although the direct injection of KYNA into the globus pallidus
internus [243, 244], or its co-infusion with either QUIN or NMDA
into the SNpc [236], resulted in beneficial effects in PD models, the
systemic administration of KYNA does not seem to be a good ther-
apeutic approach in CNS disorders for several reasons. It pene-
trates the blood–brain barrier poorly [118], and it undergoes rapid
clearance from the brain and the body, mediated by organic anion
transporters [245]. To overcome these disadvantages, numbers of
KYNA derivatives have been synthetized with preserved or
enhanced pharmacodynamic properties (reviewed in [246–248]).
Although 7-chlorokynurenic acid (7-Cl-KYNA), which has enhanced
antagonism at glycine/NMDA receptors, did not exert any protection
against the intrastriatal neurotoxic effect of MPP in rats, whereas
KYNA did [249], the systemic administration of 4-chlorokynurenine
(4-Cl-KYN), the blood–brain barrier-penetrable pro-drug of 
7-Cl-KYNA, did prevent QUIN- and malonate-induced neurotoxicity
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in the rat striatum [250]. The apparent contradiction between these
experimental findings may be resolved in that 4-Cl-KYN can be
metabolized to 4-chloro-3-hydroxyanthranilate, a powerful inhibitor
of QUIN synthesis [251], which broadens the modes of neuropro-
tective action. Furthermore, the divergence between the KYNA and
7-Cl-KYNA effects can be explained in that the halogenation of
KYNA results in compounds that are highly selective for the glycine
site of NMDARs [252] and can mainly prevent NMDAR-mediated
excitotoxicity, whereas a wider spectra of neurotransmitter recep-
tors are involved in neurodegenerative processes. The KYNA
amides seem to be excellent candidates, as they may be capable of
the selective inhibition of the NR2B subunit-containing NMDARs
too [253]. A newly synthesized KYNA amide, previously proved to
be beneficial in migraine [254] and epilepsy [255] models, exerts
neuroprotection in a transgenic mouse model of HD [256].
Concluding remarks
Although PD and HD are different clinical entities, their pathomech-
anisms reveal several common features. The main characteristic
symptoms involve disturbances in motion in both cases, with an
underlying dysfunction of the very complex motor system, mainly
the basal ganglia. Oxidative stress with mitochondrial impairment
and glutamate excitotoxicity are definitely involved in the disease
development. Although these pathogenetic factors are closely con-
nected to each other, and each can be evoked by the other, oxida-
tive stress and mitochondrial impairment appear to play the pre-
dominant role in PD pathogenesis, whereas glutamate excitotoxic-
ity does so in HD pathogenesis. Accordingly, the therapeutic strate-
gies mainly target these two possibilities. As concerns endogenous
neuroprotection, the main modes involve naturally occurring
agents and their slightly modified derivatives, and in particular sub-
stances for the achievement of antioxidant protection and the
preservation of the mitochondrial function and energy stores.
These agents, such as L-carnitine, L-carnosine, coenzyme Q10, cre-
atine, cysteamine/cystamine, EPA, -lipoic acid, pyruvate, taurine
and tocopherol, all serve as potential therapeutics. However, in
contrast with the promising preclinical findings, most of them did
not exhibit unequivocal significant efficacy in clinical trials. This
could be due to the lack of optimum dosing or an improper study
design, but it is very important to pay special attention to the valid-
ity of the experimental models and to the heterogeneity of the
human population and of the disease development. There is still a
major need for further studies with natural or newly designed
agents in order to achieve a significant level of neuroprotection, 
or at least a certain symptomatic benefit. As concerns the
kynurenines, KYNA would serve as a good anti-excitotoxic agent by
virtue of its wide-spectrum pharmacodynamic profile and low
potency of inducing side-effects. However, there is a major need to
improve the pharmacokinetic profile in order to attain an accept-
able half-life and a better blood–brain penetrance. Thanks to a sys-
tematic molecule design, KYNA derivatives will hopefully exhibit
therapeutic potency in both preclinical and clinical studies.
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